Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001507707 | SCV001713412 | uncertain significance | not provided | 2020-01-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003771548 | SCV004581433 | uncertain significance | Norman-Roberts syndrome; Familial temporal lobe epilepsy 7 | 2023-06-14 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with valine, which is neutral and non-polar, at codon 1222 of the RELN protein (p.Glu1222Val). This variant is not present in population databases (gnomAD no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RELN protein function. ClinVar contains an entry for this variant (Variation ID: 1163009). This variant has not been reported in the literature in individuals affected with RELN-related conditions. |